Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Umair Jarral"'
Publikováno v:
Blood. 134:2813-2813
BACKGROUND FL is the most common indolent non-Hodgkin lymphoma (NHL). While very responsive to therapy, it has been considered incurable. Nonetheless, pts remaining in remission >24 months appear to have a survival comparable to an age-matched popula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57246afc7954ea0d44f05ecd2cd1b995
https://doi.org/10.1182/blood-2019-127262
https://doi.org/10.1182/blood-2019-127262
Autor:
Anthony R. Mato, Bruce D. Cheson, Krish Patel, Alan P Skarbnik, Maryam Sarraf Yazdy, Hanna Weissbrot, Lori A. Leslie, Lindsey E. Roeker, Mazyar Shadman, Charlene C. Kabel, Ryan Jacobs, Andre Goy, John M. Pagel, Isaac Deonarine, Nicole Lamanna, Sarah E. Stump, Neil Bailey, Tatyana Feldman, Sirin Khajavian, Jessica Weiss, Umair Jarral, Julie Goodfriend, Chaitra S. Ujjani, Kate J Whitaker, Catherine C. Coombs, Benyam Muluneh
Publikováno v:
Blood. 134:4311-4311
Introduction: Acalabrutinib (acala) is an irreversible, second generation Bruton tyrosine kinase inhibitor (BTKi) approved by the FDA for the treatment of relapsed/refractory (R/R) mantle cell lymphoma, and is in advanced stages of clinical testing f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cbdfaf68222e7aad72bee67caa233ef
https://doi.org/10.1182/blood-2019-130062
https://doi.org/10.1182/blood-2019-130062